Ascelia Pharma AB (OSTO:ACE) Interest Income: kr2.85 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ACE Ascelia Pharma AB OSTO:ACE
18 GF Score
Price kr0.61
! 1 Warning Sign
View Full Analysis

What is Ascelia Pharma AB Interest Income?

Ascelia Pharma AB OSTO:ACE +3.39% 18 Interest Income is kr2.85 Mil as of Mar. 2026. GuruFocus rates OSTO:ACE with a GF Score™ of 18/100. The stock has 1 warning sign investors should review.

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Ascelia Pharma AB's interest income for the three months ended in Mar. 2026 was kr0.40 Mil. Its interest income for the trailing twelve months (TTM) ended in Mar. 2026 was kr2.85 Mil.

Ascelia Pharma AB Interest Income Historical Data

* Premium members only.

The historical data trend for Ascelia Pharma AB's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascelia Pharma AB Interest Income Chart

Ascelia Pharma AB Annual Data
Trend Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Income
Get a 7-Day Free Trial Premium Member Only 0.01 0.64 1.32 0.77 0.81

Ascelia Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.71 1.84 0.43 0.19 0.40
OSTO:ACE
18GF Score
Ascelia Pharma AB OSTO:ACE
Interest Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascelia Pharma AB Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr2.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Income →
What does a Interest Income of kr2.85 Mil mean?
Ascelia Pharma AB (OSTO:ACE) has a Interest Income of kr2.85 Mil as of Mar. 2026. Interest Income is the amount a company receives on savings accounts and certificates of deposits. View historical data on Ascelia Pharma AB and its competitors.
Is Ascelia Pharma AB's Interest Income too high?
Ascelia Pharma AB's current Interest Income is kr2.85 Mil. Overall, Ascelia Pharma AB has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Ascelia Pharma AB's Interest Income compare to VRTX and REGN?
Ascelia Pharma AB's Interest Income of kr2.85 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Income for a Biotechnology company?
A good Interest Income depends on the Biotechnology industry context. However, Interest Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Income mean?
A high Interest Income can signal that a stock is expensive relative to its fundamentals. Interest Income is the amount a company receives on savings accounts and certificates of deposits. View historical data on Ascelia Pharma AB and its competitors. Ascelia Pharma AB's current Interest Income is kr2.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascelia Pharma AB stock overvalued right now?
Ascelia Pharma AB (OSTO:ACE) has a current Interest Income of kr2.85 Mil. The current Interest Income is kr2.85 Mil. Ascelia Pharma AB's overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Income calculated?
Interest Income is calculated from a company's financial statements. For Ascelia Pharma AB (OSTO:ACE), the current Interest Income is kr2.85 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascelia Pharma AB Business Description

Other Exchanges ACEs:UK
Address Hyllie Boulevard 34, Malmo, SWE, 215 32
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.
18GF Score

Get the complete analysis for OSTO:ACE

Interest Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.61
Price